

**Summary of Consolidated Financial Results [IFRS]
for the First Six Months (Semi-Annual Period) of the Fiscal Year Ending March 31, 2026**

November 5, 2025

Listed company name : Sysmex Corporation
Code : 6869
Listed stock exchanges : Tokyo Stock Exchange
URL : www.sysmex.co.jp/en
Company representative : Kaoru Asano, President
Contact : Takuro Minami, Executive Vice President of
Corporate Business Administration
Phone : 078(265)-0500
Scheduled date for filing of semi-annual report : November 7, 2025
Scheduled date for dividend payment : December 2, 2025
Preparation of supplementary material for
semi-annual earnings : Yes
Holding of earnings announcement : Yes

(Unit: Millions of Yen)

1. Results for the First Six Months (Semi-Annual Period) of the Fiscal Year Ending March 31, 2026

(1) Operating results

(% changes as compared with the semi-annual period of the previous fiscal year)

	Net Sales		Operating profit		Profit before tax		Profit	
Six months ended Sep. 30, 2025	232,527	(4.1)%	32,957	(25.9)%	29,955	(21.7)%	18,862	(27.2)%
Six months ended Sep. 30, 2024	242,479	14.0%	44,502	31.6%	38,280	15.0%	25,923	17.0%

	Profit attributable to owners of the parent		Total comprehensive income		Basic earnings per share (Yen)	Diluted earnings per share (Yen)
Six months ended Sep. 30, 2025	19,019	(26.9)%	30,038	71.3%	30.50	30.50
Six months ended Sep. 30, 2024	26,002	17.2%	17,536	(56.4)%	41.70	41.70

(2) Financial condition

	Total assets	Total equity	Equity attributable to owners of the parent	Equity attributable to owners of the parent to total assets
As of Sep. 30, 2025	669,410	483,156	482,554	72.1%
As of Mar. 31, 2025	665,268	464,534	463,776	69.7%

2. Dividend

	Dividend per share				
	First quarter (Yen)	Second quarter (Yen)	Third quarter (Yen)	Year-end (Yen)	Annual (Yen)
Year ended Mar. 31, 2025	—	15.00	—	17.00	32.00
Year ending Mar. 31, 2026	—	19.00			
Year ending Mar. 31, 2026 (Forecast)			—	19.00	38.00

Notes:

- Revision of dividends forecast for this period: No
- Details of the dividends for the fiscal year ending March 31, 2026

Second quarter	Ordinary dividend:	¥18.00
	Commemorative dividend:	¥1.00 (30th anniversary of listing)
Year-end	Ordinary dividend:	¥18.00
	Commemorative dividend:	¥1.00 (30th anniversary of listing)

3. Financial Forecast for the Year Ending March 31, 2026

(% changes as compared with the previous fiscal year)

	Net Sales		Operating profit		Profit before tax		Profit attributable to owners of the parent		Basic earnings per share (Yen)
Year ending Mar. 31, 2026	510,000	0.3%	76,000	(13.2)%	71,000	(10.4)%	45,000	(16.2)%	72.19

Note: Revision of financial forecast for this period: Yes

4. Other Information

- Significant changes in scope of consolidation: No
- Changes in accounting policies and accounting estimates
 - Changes in accounting policies required by IFRS: No
 - Other changes in accounting policies: No
 - Changes in accounting estimates: No
- Number of outstanding stock (common stock)
 - Number of outstanding stock at the end of each fiscal period (including treasury stock):
629,480,076 shares as of Sep.30, 2025; 629,473,176 shares as of Mar. 31, 2025
 - Number of treasury stock at the end of each fiscal period:
6,300,045 shares as of Sep. 30, 2025; 5,873,371 shares as of Mar. 31, 2025
 - Average number of outstanding stock for each period (semi-annual period):
623,485,229 shares for the six months ended Sep. 30, 2025
623,498,618 shares for the six months ended Sep. 30, 2024

Note: The Company has introduced Executive Compensation BIP Trust and Stock-Granting Employee Stock Ownership Plan (ESOP) Trust. Company shares held by the trust are included in treasury stock and are excluded from calculations of the number of treasury stock at the end of the fiscal period and the average number of outstanding stock for the period.

* Summaries of semi-annual financial results are exempt from review conducted by certified public accountants or an audit firm.

* Explanation regarding the appropriate use of financial forecast and other information

1. The forecasts and future projections contained herein have been prepared on the basis of rational decisions given the information available as of the date of announcement of this document. These forecasts do not represent a commitment by the Company, and actual performance may differ substantially from forecasts for a variety of reasons. Please refer to “3) Consolidated financial forecast” within “1. Qualitative information on semi-annual financial results” on page 4 of the attachment to this document for cautionary statements concerning the conditions and performance forecasts that serve as the basis for these forecasts.
2. Supplementary financial materials (in Japanese and English) will be posted on the Sysmex website on Wednesday, November 5, 2025.

Content of Supplementary Materials

1. Qualitative information on semi-annual financial results	2
1) Operating performance analysis	2
2) Financial conditions analysis	3
3) Consolidated financial forecast	4
2. Condensed semi-annual consolidated financial statements and notes	5
1) Condensed semi-annual consolidated statement of financial position	5
2) Condensed semi-annual consolidated statement of income	7
3) Condensed semi-annual consolidated statement of comprehensive income	8
4) Condensed semi-annual consolidated statement of changes in equity	9
5) Condensed semi-annual consolidated statement of cash flows	10
6) Notes to the condensed semi-annual consolidated financial statements	11
1. Notes related to the going concern assumption	11
2. Segment information	11

1. Qualitative information on semi-annual financial results

Future-related information contained in the text below is based on the Company's judgement as of the end of the fiscal period under review.

1) Operating performance analysis

The Group's consolidated financial results for the first six months of the fiscal year ending March 31, 2026 are as follows.

Net sales by destination

	Six months ended Sep. 30, 2024		Six months ended Sep. 30, 2025		YoY (Previous period = 100)
	Amount (Millions of yen)	Percentage of total (%)	Amount (Millions of yen)	Percentage of total (%)	
Japan	30,323	12.5	25,435	10.9	83.9
Americas	63,745	26.3	64,686	27.8	101.5
EMEA (Europe, the Middle East, and Africa)	69,121	28.5	72,968	31.4	105.6
China	54,540	22.5	43,282	18.7	79.4
AP (Asia Pacific)	24,748	10.2	26,153	11.2	105.7
Overseas subtotal	212,156	87.5	207,092	89.1	97.6
Total	242,479	100.0	232,527	100.0	95.9

In Japan, we experienced lower sales of hematology instruments and immunochemistry and hemostasis reagents. As a result, sales in Japan fell 16.1% year on year, to ¥25,435 million. The ratio of sales in Japan decreased 1.6 percentage points, to 10.9%.

Overseas, sales of hematology instruments, reagents, and maintenance services declined. This factor, coupled with appreciation of the yen in foreign exchange markets, caused overseas sales to fall 2.4%, to ¥207,092 million. The overseas sales ratio rose 1.6 percentage points, to 89.1%.

Selling, general and administrative (SG&A) expenses totaled ¥77,873 million, up 7.6% year on year, due primarily to an increase in personnel associated with business expansion, as well as higher amortization expenses related to investments in digital infrastructure. R&D expenses came to ¥13,203 million, down 13.4%.

As a result, on a consolidated basis for the first six months of the fiscal year ending March 31, 2026, net sales amounted to ¥232,527 million (down 4.1% year on year), operating profit was ¥32,957 million (down 25.9%), profit before tax was ¥29,955 million (down 21.7%), and profit attributable to owners of the parent totaled ¥19,019 million (down 26.9%).

Performance by segment

(1) Headquarters

In South Korea, sales of hematology instruments increased; but in Japan, sales of hematology instruments declined, as did sales of immunochemistry and hemostasis reagents. In the medical robotics business, sales of maintenance services grew, but sales of instruments decreased. Consequently, sales fell 11.5% year on year, to ¥38,371 million.

On the profit front, in addition to the decline in sales, a worsening cost of sales ratio and an increase in SG&A expenses led to a segment profit (operating profit) of ¥11,874 million (down 57.0%).

(2) Americas RHQ

In North America, sales of urinalysis instruments, maintenance services, and hematology instruments rose. In Central and South America, sales of urinalysis instruments and reagents rose, while sales of hematology instruments declined. As a result, sales in the Americas were up 2.3% year on year, to ¥61,164 million.

Despite the higher sales, segment profit (operating profit) was ¥3,175 million, essentially flat year on year (down 0.1%), as selling, general and administrative (SG&A) expenses rose as personnel increased in line with business expansion.

(3) EMEA RHQ

Sales of hematology and urinalysis instruments and reagents increased, bolstering sales by 6.1% year on year, to ¥70,531 million.

Gross profit rose on the back of higher sales, but SG&A expenses grew in tandem with business expansion. As a result, segment profit (operating profit) decreased 15.7% year on year, to ¥5,721 million.

(4) China RHQ

Sales of hemostasis instruments and reagents increased. However, amid a difficult operating environment stemming from government-led policies to curtail medical expenses, sales of hematology instruments and reagents fell. As a result, segment sales were ¥43,227 million, down 20.6% year on year.

Although an improved cost of sales ratio and lower SG&A expenses had a positive impact on profit, lower sales caused segment profit (operating profit) to fall 2.1% year on year, to ¥5,688 million.

(5) Asia Pacific RHQ

In the hematology field, sales of instruments and maintenance services decreased, while reagent sales grew. Sales of hemostasis and urinalysis reagents also rose. Accordingly, sales expanded 4.6%, to ¥19,232 million.

Despite the higher sales, segment profit (operating profit) decreased 3.1%, to ¥3,626 million, as the cost of sales ratio deteriorated owing to such factors as depreciation on our new production site in India, which was completed in August 2024.

2) Financial conditions analysis

(1) Financial conditions

As of September 30, 2025, total assets amounted to ¥669,410 million, up ¥4,141 million from March 31, 2025. As main factors, although trade and other receivables (current assets) decreased ¥12,708 million, inventories increased ¥9,529 million, and property, plant and equipment rose ¥5,328 million.

Meanwhile, total liabilities decreased by ¥14,480 million from March 31, 2025, to ¥186,253 million. The main factors included reductions of ¥4,663 million in income taxes payable, ¥4,440 million in accrued bonuses, ¥3,179 million in trade and other payables, and ¥1,507 million in accrued expenses.

Total equity increased by ¥18,622 million from March 31, 2025, to ¥483,156 million. Among principal reasons, other components of equity increased ¥11,217 million and retained earnings increased ¥8,376 million. The equity attributable to owners of the parent to total assets rose 2.4 percentage points, from 69.7% as of March 31, 2025, to 72.1%.

(2) Cash flows

As of September 30, 2025, cash and cash equivalents amounted to ¥86,101 million, down ¥3,468 million from March 31, 2025.

Cash flows from various activities during the first six months of the fiscal year are described in more detail below.

(Cash flows from operating activities)

Net cash provided by operating activities was ¥38,062 million, down ¥12,069 million from the first six months of the preceding fiscal year. As principal factors, profit before tax provided ¥29,955 million (¥8,324 less than in the corresponding period of the preceding fiscal year), depreciation and amortization provided ¥22,832 million (up ¥3,641 million), a decrease in trade receivable provided ¥15,791 million (down ¥802 million), an increase in inventories used ¥6,905 million (down ¥508 million), and income taxes paid used ¥14,389 million (up ¥934 million).

(Cash flows from investing activities)

Net cash used in investing activities was ¥26,604 million (up ¥2,845 million). Among major factors, purchases of property, plant and equipment used ¥15,645 million (up ¥4,154 million), and

purchases of intangible assets used ¥10,011 million (down ¥1,834 million).

(Cash flows from financing activities)

Net cash used in financing activities was ¥17,577 million (up ¥7,044 million). This was mainly due to dividends paid of ¥10,601 million (up ¥1,872 million), and repayments of lease liabilities of ¥5,789 million (up ¥781 million).

3) Consolidated financial forecast

For the Company's consolidated financial forecast for the full fiscal year, please refer to the Announcement Regarding Differences between Actual and Forecast Figures for the Six Months Ended September 30, 2025, and Notice of Revision to the Full-Year Financial Forecast, announced today (November 5, 2025).

2. Condensed semi-annual consolidated financial statements and notes

1) Condensed semi-annual consolidated statement of financial position

(Unit: Millions of yen)

	As of March 31, 2025	As of September 30, 2025
Assets		
Current assets		
Cash and cash equivalents	89,570	86,101
Trade and other receivables	163,007	150,298
Inventories	81,811	91,340
Other short-term financial assets	654	351
Income taxes receivable	1,246	1,957
Other current assets	28,531	28,917
Total current assets	364,821	358,967
Non-current assets		
Property, plant and equipment	130,211	135,539
Goodwill	14,205	14,834
Intangible assets	92,146	93,325
Investments accounted for using the equity method	339	243
Trade and other receivables	26,978	29,351
Other long-term financial assets	12,034	13,958
Asset for retirement benefits	0	41
Other non-current assets	6,880	6,971
Deferred tax assets	17,651	16,176
Total non-current assets	300,447	310,443
Total assets	665,268	669,410

(Unit: Millions of yen)

	As of March 31, 2025	As of September 30, 2025
Liabilities and equity		
Liabilities		
Current liabilities		
Trade and other payables	31,865	28,685
Lease liabilities	9,250	9,309
Other current financial liabilities	1,403	1,323
Income taxes payable	12,784	8,121
Provisions	1,164	1,122
Contract liabilities	18,098	17,363
Accrued expenses	22,355	20,848
Accrued bonuses	14,709	10,269
Other current liabilities	11,194	10,462
Total current liabilities	122,826	107,505
Non-current liabilities		
Long-term loans payable	32,359	32,003
Lease liabilities	23,126	22,295
Other non-current financial liabilities	56	46
Liability for retirement benefits	2,127	2,362
Provisions	1,054	1,259
Other non-current liabilities	11,608	12,017
Deferred tax liabilities	7,575	8,763
Total non-current liabilities	77,908	78,747
Total liabilities	200,734	186,253
Equity		
Equity attributable to owners of the parent		
Capital stock	14,887	14,898
Capital surplus	20,960	20,981
Retained earnings	402,820	411,197
Treasury stock	(12,318)	(13,165)
Other components of equity	37,425	48,643
Total equity attributable to owners of the parent	463,776	482,554
Non-controlling interests	758	602
Total equity	464,534	483,156
Total liabilities and equity	665,268	669,410

2) Condensed semi-annual consolidated statement of income

(Unit: Millions of yen)

	Six months ended September 30, 2024	Six months ended September 30, 2025
Net sales	242,479	232,527
Cost of sales	111,184	109,970
Gross profit	131,295	122,556
Selling, general and administrative expenses	72,371	77,873
Research and development expenses	15,239	13,203
Other operating income	1,191	1,974
Other operating expenses	373	496
Operating profit	44,502	32,957
Financial income	520	441
Financial expenses	1,421	1,814
Share of profit (loss) of associates accounted for using the equity method	(1,290)	(938)
Foreign exchange gain (loss)	(4,030)	(689)
Profit before tax	38,280	29,955
Income taxes expenses	12,357	11,092
Profit	25,923	18,862
Profit attributable to		
Owners of the parent	26,002	19,019
Non-controlling interests	(79)	(156)
Profit	25,923	18,862

(Unit: Yen)

Earnings per share		
Basic	41.70	30.50
Diluted	41.70	30.50

3) Condensed semi-annual consolidated statement of comprehensive income

(Unit: Millions of yen)

	Six months ended September 30, 2024	Six months ended September 30, 2025
Profit	25,923	18,862
Other comprehensive income		
Items that will not be reclassified subsequently to profit or loss		
Net gain (loss) on financial assets measured at fair value through other comprehensive income	(1,550)	585
Total	(1,550)	585
Items that may be reclassified subsequently to profit or loss		
Exchange differences on translation of foreign operations	(6,826)	10,573
Share of other comprehensive income of investments accounted for using the equity method	(9)	16
Total	(6,836)	10,590
Total other comprehensive income	(8,386)	11,175
Comprehensive income	17,536	30,038
Comprehensive income attributable to		
Owners of the parent	17,616	30,194
Non-controlling interests	(79)	(156)
Comprehensive income	17,536	30,038

4) Condensed semi-annual consolidated statement of changes in equity
Six months ended September 30, 2024

(Unit: Millions of yen)

	Equity attributable to owners of the parent						Non-controlling interests	Total equity
	Capital stock	Capital surplus	Retained earnings	Treasury stock	Other components of equity	Total		
As of April 1, 2024	14,729	20,830	365,985	(12,315)	42,814	432,045	851	432,897
Profit	—	—	26,002	—	—	26,002	(79)	25,923
Other comprehensive income	—	—	—	—	(8,386)	(8,386)	—	(8,386)
Comprehensive income	—	—	26,002	—	(8,386)	17,616	(79)	17,536
Exercise of warrants	2	1	—	—	—	3	—	3
Share-based payment transactions	—	14	—	—	—	14	—	14
Cash dividends	—	—	(8,728)	—	—	(8,728)	—	(8,728)
Purchase of treasury stock	—	—	—	(2)	—	(2)	—	(2)
Disposal of treasury stock	—	0	—	0	—	0	—	0
Transfer to retained earnings	—	—	1,361	—	(1,361)	—	—	—
Total transactions with the owners	2	15	(7,367)	(2)	(1,361)	(8,713)	—	(8,713)
As of September 30, 2024	14,732	20,846	384,620	(12,318)	33,066	440,948	772	441,720

Six months ended September 30, 2025

(Unit: Millions of yen)

	Equity attributable to owners of the parent						Non-controlling interests	Total equity
	Capital stock	Capital surplus	Retained earnings	Treasury stock	Other components of equity	Total		
As of April 1, 2025	14,887	20,960	402,820	(12,318)	37,425	463,776	758	464,534
Profit	—	—	19,019	—	—	19,019	(156)	18,862
Other comprehensive income	—	—	—	—	11,175	11,175	—	11,175
Comprehensive income	—	—	19,019	—	11,175	30,194	(156)	30,038
Exercise of warrants	10	6	—	—	—	16	—	16
Share-based payment transactions	—	46	—	—	—	46	—	46
Cash dividends	—	—	(10,601)	—	—	(10,601)	—	(10,601)
Purchase of treasury stock	—	—	—	(877)	—	(877)	—	(877)
Disposal of treasury stock	—	(31)	—	31	—	—	—	—
Transfer to retained earnings	—	—	(41)	—	41	—	—	—
Total transactions with the owners	10	20	(10,642)	(846)	41	(11,416)	—	(11,416)
As of September 30, 2025	14,898	20,981	411,197	(13,165)	48,643	482,554	602	483,156

5) Condensed semi-annual consolidated statement of cash flows

(Unit: Millions of yen)

	Six months ended September 30, 2024	Six months ended September 30, 2025
Cash flows from operating activities		
Profit before tax	38,280	29,955
Depreciation and amortization	19,191	22,832
Share of loss (profit) of associates accounted for using the equity method	1,290	938
Loss on retirement of non-current assets	64	157
Decrease (increase) in trade receivable	16,593	15,791
Decrease (increase) in advance payments	326	(962)
Decrease (increase) in inventories	(7,414)	(6,905)
Increase (decrease) in trade payable	(1,648)	215
Increase (decrease) in accounts payable—other	(1,758)	(2,453)
Increase (decrease) in contract liabilities	361	(986)
Increase (decrease) in accrued expenses	(417)	(1,927)
Decrease/increase in consumption taxes receivable/payable	419	1,887
Increase (decrease) in accrued bonuses	(2,039)	(4,464)
Other—net	869	(817)
Subtotal	64,118	53,260
Interest and dividend received	284	290
Interest paid	(816)	(1,098)
Income taxes paid	(13,455)	(14,389)
Net cash provided by (used in) operating activities	50,131	38,062
Cash flows from investing activities		
Purchases of property, plant and equipment	(11,490)	(15,645)
Purchases of intangible assets	(11,845)	(10,011)
Payments resulting in an increase in long-term prepaid expenses	(326)	(400)
Purchases of investments in equity instruments	(1,933)	(49)
Proceeds from the sale of equity instruments	1,853	0
Purchase of investments in debt instruments	(399)	(1,179)
Payments into time deposits	(872)	(352)
Proceeds from withdrawal of time deposits	1,007	539
Other—net	249	495
Net cash provided by (used in) investing activities	(23,758)	(26,604)
Cash flows from financing activities		
Proceeds from long-term loans payable	3,500	—
Repayments of long-term loans payable	(296)	(356)
Exercise of warrants	3	16
Purchase of treasury shares	(2)	(877)
Dividends paid	(8,728)	(10,601)
Repayments of lease liabilities	(5,008)	(5,789)
Other—net	0	31
Net cash provided by (used in) financing activities	(10,532)	(17,577)
Effects of exchange rate changes on cash and cash equivalents	371	2,651
Net increase (decrease) in cash and cash equivalents	16,211	(3,468)
Cash and cash equivalents at the beginning of the term	75,507	89,570
Cash and cash equivalents at the end of the term	91,719	86,101

6) Notes to the condensed semi-annual consolidated financial statements

1. Notes related to the going concern assumption

Not applicable

2. Segment information

1) Overview of reportable segments

The reportable segments of the Company and its subsidiaries (the Group) are the constituent business units of the Group for which separate financial data are available and that are examined on a regular basis for the purpose of enabling the Managing Board to allocate managerial resources and evaluate results of operations.

The Group is primarily engaged in the manufacture and sale of diagnostic instruments and reagents. These businesses are conducted in Japan and East Asia by Sysmex and in the Americas, EMEA, China, and the Asia Pacific by regional headquarters established therein. These companies formulate comprehensive strategies tailored to regional characteristics and conduct business activities accordingly. Some overseas subsidiaries are managed by Sysmex depending on the nature of their business.

The five managing company-specific segments are “Headquarters,” “Americas RHQ,” “EMEA RHQ,” “China RHQ,” and “AP RHQ.”

The companies included in these reportable segments are outlined below.

Reportable segments	Companies included in the reportable segments
Headquarters	Sysmex Corporation, Sysmex RA Co., Ltd., 12 other domestic subsidiaries, Oxford Gene Technology IP Limited, Sysmex Partec GmbH, Sysmex Korea Co., Ltd., 12 other overseas subsidiaries
Americas RHQ	Sysmex America, Inc., Sysmex Reagents America, Inc., Sysmex do Brasil Industria e Comercio Ltda., five other subsidiaries in the Americas
EMEA RHQ	Sysmex Europe SE, Sysmex Deutschland GmbH, Sysmex UK Limited, Sysmex France S.A.S., 26 other subsidiaries in the EMEA region
China RHQ	Sysmex Shanghai Ltd., Jinan Sysmex Medical Electronics Co., Ltd., two other subsidiaries in China
AP RHQ	Sysmex Asia Pacific Pte Ltd., Sysmex India Pvt. Ltd., nine other subsidiaries in the Asia Pacific region

2) Segment profit and operating results

Profit and operating results from continuing operations by reportable segment of the Group are as follows:

Intersegment sales are determined based on market prices or costs of goods manufactured.

Accounting policies of reporting segments are consistent with the Group’s accounting policies indicated in the consolidated financial statements for the previous fiscal year.

Six months ended September 30, 2024

(Unit: Millions of yen)

	Reportable segment						Adjustments (Note 1)	Consolidated (Note 2)
	Head- quarters	Americas RHQ	EMEA RHQ	China RHQ	AP RHQ	Total		
Sales								
Sales to external customers	43,336	59,804	66,482	54,471	18,384	242,479	—	242,479
Intersegment sales	75,881	9	300	313	21	76,527	(76,527)	—
Total	119,218	59,814	66,782	54,785	18,405	319,007	(76,527)	242,479
Segment profit (loss)	27,595	3,178	6,785	5,812	3,740	47,111	(2,609)	44,502
Financial income	—	—	—	—	—	—	—	520
Financial expenses	—	—	—	—	—	—	—	1,421
Share of profit (loss) of associates accounted for using the equity method	—	—	—	—	—	—	—	(1,290)
Foreign exchange gain (loss)	—	—	—	—	—	—	—	(4,030)
Profit before tax	—	—	—	—	—	—	—	38,280
Income taxes expenses	—	—	—	—	—	—	—	12,357
Profit	—	—	—	—	—	—	—	25,923

Notes:

1. Segment profit (loss) adjustments of negative ¥2,609 million include negative ¥2,448 million for the unrealized gains on inventories and negative ¥161 million for the unrealized gains on non-current assets.
2. Segment profit (loss) is adjusted to coincide with operating profit in the condensed semi-annual consolidated statement of income.

Six months ended September 30, 2025

(Unit: Millions of yen)

	Reportable segment						Adjustments (Note 1)	Consolidated (Note 2)
	Head- quarters	Americas RHQ	EMEA RHQ	China RHQ	AP RHQ	Total		
Sales								
Sales to external customers	38,371	61,164	70,531	43,227	19,232	232,527	—	232,527
Intersegme nt sales	62,024	13	274	169	22	62,505	(62,505)	—
Total	100,395	61,177	70,806	43,397	19,255	295,033	(62,505)	232,527
Segment profit (loss)	11,874	3,175	5,721	5,688	3,626	30,086	2,871	32,957
Financial income	—	—	—	—	—	—	—	441
Financial expenses	—	—	—	—	—	—	—	1,814
Share of profit (loss) of associates accounted for using the equity method	—	—	—	—	—	—	—	(938)
Foreign exchange gain (loss)	—	—	—	—	—	—	—	(689)
Profit before tax	—	—	—	—	—	—	—	29,955
Income taxes expenses	—	—	—	—	—	—	—	11,092
Profit	—	—	—	—	—	—	—	18,862

Notes:

1. Segment profit (loss) adjustments of ¥2,871 million include ¥2,917 million for the unrealized gains on inventories and negative ¥46 million for the unrealized gains on non-current assets.
2. Segment profit (loss) is adjusted to coincide with operating profit in the condensed semi-annual consolidated statement of income.